Literature DB >> 7353186

Porcine malignant hyperthermia--failure of dantrolene dose response to diagnose susceptibility (halothane effect).

E H Flewellen, T E Nelson, D E Bee.   

Abstract

Dantrolene, a skeletal muscle relaxant, has been proven prophylactic and therapeutic for malignant hyperthermia (MH) in swine. This study examined the feasibility of using a dantrolene dose response as measured by indirectly evoked foretoe twitch depression as a means to safely discriminate MH susceptibility in swine. The effect of halothane on the dantrolene response was quantified. Subjects were five Poland China malignant hyperthermia susceptible (MHS) and five Hampshire malignant hyperthermia resistant (MHR) swine. Dantrolene dose response was determined twice in each anaesthetized subject, once with thiopentone and subsequently with thiopentone and halothane. Dantrolene in incremental doses, 0.15 mg.kg-1, was given to a cumulative dose of 2--3 mg.kg-1. Under thiopentone anaesthesia, the dantrolene dose responses were similar in MHS and MHR animals. The presence of halothane augmented dantrolene twitch depression in MHS but not MHR animals when compared to their response under thiopentone. Under halothane, the MHS animals had significantly augmented dantrolene response compared to MHR pigs, but three MHS animals had developed the MH syndrome prior to receiving dantrolene. We conclude that dantrolene muscle relaxant dose response cannot be used as a diagnostic test for MHS in swine. Halothane augments dantrolene twitch depression in MHS swine.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7353186     DOI: 10.1007/bf03006842

Source DB:  PubMed          Journal:  Can Anaesth Soc J        ISSN: 0008-2856


  18 in total

1.  Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium.

Authors:  G G Harrison
Journal:  Br J Anaesth       Date:  1975-01       Impact factor: 9.166

2.  Screening of malignant hyperthermia susceptible families by creatine phosphokinase measurement and other clinical investigations.

Authors:  B A Britt; L Endrenyi; P L Peters; F H Kwong; L Kadijevic
Journal:  Can Anaesth Soc J       Date:  1976-05

3.  Studies on the mechanism of action of dantrolene sodium. A skeletal muscle relaxant.

Authors:  K O Ellis; J F Carpenter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1972       Impact factor: 3.000

4.  Screening for malignant hyperpyrexia.

Authors:  F R Ellis; N P Keaney; D G Harriman; D W Sumner; K Kyei-Mensah; J H Tyrrell; J B Hargreaves; R K Parikh; P L Mulrooney
Journal:  Br Med J       Date:  1972-09-02

5.  Halothane-induced porcine malignant hyperthermia: metabolic and hemodynamic changes.

Authors:  G A Gronert; R A Theye
Journal:  Anesthesiology       Date:  1976-01       Impact factor: 7.892

6.  The mechanism of action of dantrolene sodium.

Authors:  K G Morgan; S H Bryant
Journal:  J Pharmacol Exp Ther       Date:  1977-04       Impact factor: 4.030

7.  Dantrolene in porcine malignant hyperthermia.

Authors:  G A Gronert; J H Milde; R A Theye
Journal:  Anesthesiology       Date:  1976-06       Impact factor: 7.892

8.  The adenosine triphosphate (ATP) depletion test: comparison with the caffeine contracture test as a method of diagnosing malignant hyperthermia susceptibility.

Authors:  B A Britt; L Endrenyi; W Kalow; P L Peters
Journal:  Can Anaesth Soc J       Date:  1976-11

9.  Rationale for dantrolene vs. procainamide for treatment of malignant hyperthermia.

Authors:  T E Nelson; E H Flewellen
Journal:  Anesthesiology       Date:  1979-02       Impact factor: 7.892

10.  In vivo neutron activation analysis for bone calcium (INVAA) in malignant hyperthermia susceptible patients.

Authors:  B A Britt; J E Harrison; K G McNeill
Journal:  Can Anaesth Soc J       Date:  1979-03
View more
  3 in total

1.  Pharmacological distinction between dantrolene and ryanodine binding sites: evidence from normal and malignant hyperthermia-susceptible porcine skeletal muscle.

Authors:  S S Palnitkar; J R Mickelson; C F Louis; J Parness
Journal:  Biochem J       Date:  1997-09-15       Impact factor: 3.857

Review 2.  Dantrolene.

Authors:  B A Britt
Journal:  Can Anaesth Soc J       Date:  1984-01

Review 3.  Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.

Authors:  A Ward; M O Chaffman; E M Sorkin
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.